map-image

SCINTOMICS ONLINE
-news and infos- 

NEWS IN BRIEF

Radiohybrid PSMA-targeted Agents for Prostate Cancer licensed to Blue Earth Diagnostics

MUNICH, May 2018 – SCINTOMICS has signed an exclusive, worldwide agreement with Blue Earth Diagnostics, a leading molecular imaging diagnostics company. Under the terms of the agreement, Blue Earth Diagnostics has acquired the exclusive worldwide rights to a broad family of Prostate Specific Membrane Antigen (PSMA)-targeted radiohybrid (“rh”) agents for cancer imaging, together with an exclusive option to explore therapeutic applications.
Read more

FAQ: Can we establish Radiohybrid-PSMA in our hospital ?

YES, you can !
If you like to exploit the outstanding features of the F-18 or Ga-68-Radiohybrid PSMA inhibitors in your hospital press the ´read more´ bottom below or contact or give us a call. Read more

PSNM2018


23.-26.05.2018 SZCZECIN(Poland)

AGRR 2018


20.-22.09.2018 Aachen(Germany)

EANM2018


13.-17.10.2017 Düsseldorf(Germany)